表紙
市場調査レポート

自己免疫疾患治療市場:2017年までの予測 - 多発性硬化症および全身性エリテマトーデス治療分野の成長に寄与するジレニアおよびベンリスタの発売

Autoimmune Disorders Therapeutics Market to 2017 - Launch of Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis and Systemic Lupus Erythematosus Therapeutic Segments

発行 GBI Research 商品コード 239938
出版日 ページ情報 英文 183 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
自己免疫疾患治療市場:2017年までの予測 - 多発性硬化症および全身性エリテマトーデス治療分野の成長に寄与するジレニアおよびベンリスタの発売 Autoimmune Disorders Therapeutics Market to 2017 - Launch of Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis and Systemic Lupus Erythematosus Therapeutic Segments
出版日: 2012年04月30日 ページ情報: 英文 183 Pages
概要

当レポートでは、自己免疫疾患治療市場に注目し、その主要地域である米国、欧州(英国、ドイツ、フランス、イタリア、スペイン)、日本における分析データを提供するほか、2002-2010年の推移データおよび2016年までの世界市場予測、世界的市場規模、市場シェア、販売数量、療法採用パターン(有病人口、治療希望人口、受診人口、処方人口など)、治療薬の競合状況についての最新情報を集め、概略以下の構成でお届けします。

第1章 目次

  • 表一覧
  • 図一覧

第2章 2017年までの自己免疫疾患治療市場 - イントロダクション

第3章 2017年までの自己免疫疾患治療市場 - 市場概要

  • イントロダクション
    • 収益
    • 年間治療費
    • 療法の採用パターン

第4章 2017年までの自己免疫疾患治療市場:地理的様相

  • 地域別収益分析
  • 米国
    • 収益
    • 年間治療費
    • 療法の採用パターン
  • 欧州主要5カ国
  • 日本

第5章 2017年までの自己免疫疾患治療市場:治療環境

  • 関節リウマチ治療市場
    • イントロダクション
    • 収益
    • 治療アルゴリズム
    • 年間治療費
    • 療法の採用パターン
    • 治療市場に対する推進要因と障害
  • 多発性硬化症治療市場
  • 乾癬治療市場
  • 炎症性大腸炎治療市場
  • 全身性エリテマトーデス治療市場

第6章 2017年までの自己免疫疾患治療市場:パイプライン分析

  • イントロダクション
  • 自己免疫疾患治療市場 - 開発の臨床段階でのパイプライン評価
    • 申請済み分子
    • 第3相
    • 第2相
    • 第1相
    • 前臨床相
    • 創薬相
  • 自己免疫疾患治療市場における有望分子のプロフィール
    • ABT-874
    • Actemra
    • Biferonex
    • Fampyra
    • Iguratimod
    • LAS41002
    • MAbThera
    • Rebif
    • Remicade
    • Simponi
    • T-614
    • Zushima

第7章 2017年までの自己免疫疾患治療市場:競合企業プロフィール分析

  • 市場シェア分析
  • 競合企業プロフィール分析
    • Abbott Laboratories
    • Pfizer Inc.
    • Johnson & Johnson
    • Biogen Idec Inc.
    • Amgen Inc.
    • Bayer AG
    • Sanofi

第8章 2017年までの自己免疫疾患治療市場:戦略的企業再編

  • 概要
  • M&A
  • 共同開発契約
  • ライセンス契約
  • 第9章 2017年までの自己免疫疾患治療市場:付録
  • 市場の定義
  • 略語
  • 出典
  • 調査方法
  • 治療環境
  • 地理的様相
  • パイプライン分析
  • 競合環境
  • 監修
  • お問い合わせ先
  • 免責事項

図表

目次

Summary

GBI Research, the leading business intelligence provider, has released its latest research "Autoimmune Disorders Therapeutics Market to 2017 - Launch of Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis and Systemic Lupus Erythematosus Therapeutic Segments", which provides insights into autoimmune disease therapeutics market until 2017. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. The report provides in-depth analysis of the main autoimmune diseases, which are Rheumatoid Arthritis (RA), Multiple Sclerosis (MS), Psoriasis, Inflammatory Bowel Disease (IBD) including Crohn's Disease (CD) and Ulcerative Colitis (UC), and Systemic Lupus Erythematosus (SLE). The report also gives the share of generic drugs in global autoimmune diseases, as well as in each indication's market. It examines global autoimmune diseases treatment usage patterns and the geographical distribution of autoimmune diseases and the markets in the US, the top five countries of Europe, and Japan. The report also includes insights into the R&D product pipeline and explores the competitive landscape with profiles of major players. Finally, it includes analysis of Mergers and Acquisitions (M&A) and licensing agreements that have taken place in autoimmune diseases therapeutics market from 2009 to 2011.

GBI Research's analysis shows that the autoimmune disorders therapeutics market, comprising RA, MS, psoriasis, IBDs (CD and UC) and SLE, was worth $16.9 billion in 2002 and grew at a Compound Annual Growth Rate (CAGR) of 7.5% to $30.2 billion in 2010. It is forecast to reach $61.4 billion in 2017, indicating a CAGR of 10.7% during the forecast period. The average Annual Cost of Treatment (ACT) for autoimmune disorders therapeutics is increasing, and is expected to reach $12,073 by 2017, resulting in steady increase of the overall market during the forecast period. Growth in the major markets of the US, the top five countries of Europe, and Japan was driven by new developments that have created more treatment options for these indications. The future of the global market is therefore based on the success of the drugs in the pipeline.

Scope

  • Data and analysis on the autoimmune diseases therapeutics market in the leading geographies: the US, the top five countries of Europe (the UK, Germany, France, Italy, Spain), and Japan.
  • Annualized market data for the autoimmune diseases therapeutics market from 2002 to 2010, and forecast from 2010 to 2017.
  • Market data on the geographical landscape and therapeutic landscape, including market size, market share, ACT, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
  • Generic share of the global autoimmune diseases therapeutics market and for the market of each indication that is covered in the report.
  • Key drivers and restraints that have had a significant impact on the market.
  • The competitive landscape of the global autoimmune diseases market including top companies benchmarking. The key companies studied in this report are Abbott Laboratories, Amgen Inc., Johnson & Johnson, GlaxoSmithKline, AstraZeneca, Merck, Pfizer Inc., Boehringer Ingelheim and Sanofi.
  • Key M&A activities and licensing agreements that took place from 2009 to 2011 in the autoimmune diseases therapeutics market.

Reasons to buy

  • Align product portfolios to the markets with high growth potential.
  • Build effective strategies to launch pipeline products by identifying potential geographies.
  • Exploit in-licensing and out-licensing opportunities by identifying products that might fill portfolio gaps.
  • Develop key strategic initiatives by studying the key strategies of top competitors.
  • Device a more tailored country strategy through the understanding of key drivers and barriers and market potential of each indication.
  • Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
  • Reinforce R&D pipelines by identifying new target mechanisms that can produce safer and more efficacious first-in-class molecules.

Table of Contents

1 Table of Contents 3

  • 1.1 List of Tables 6
  • 1.2 List of Figures 9

2 Autoimmune Disorders Therapeutics Market to 2017 - Introduction 12

  • 2.1 GBI Research Report Guidance 13

3 Autoimmune Disorders Therapeutics Market to 2017 - Market Overview 14

  • 3.1 Introduction 14
    • 3.1.1 Revenue 14
    • 3.1.2 Annual Cost of Treatment 15
    • 3.1.3 Treatment Usage Pattern 16

4 Autoimmune Disorders Therapeutics Market to 2017: Geographical Landscape 18

  • 4.1 Revenue Analysis by Geography 18
  • 4.2 The US 19
    • 4.2.1 Revenue 19
    • 4.2.2 Annual Cost of Treatment 20
    • 4.2.3 Treatment Usage Patterns 21
  • 4.3 Top Five Countries of Europe 23
    • 4.3.1 Revenue 23
    • 4.3.2 Revenue by Country 24
    • 4.3.3 Annual Cost of Treatment 25
    • 4.3.4 Treatment Usage Patterns 26
  • 4.4 Japan 28
    • 4.4.1 Revenue 28
    • 4.4.2 Annual Cost of Treatment 29
    • 4.4.3 Treatment Usage Patterns 30

5 Autoimmune Disorders Therapeutics Market to 2017: Therapeutic Landscape 32

  • 5.1 Rheumatoid Arthritis Therapeutics Market 32
    • 5.1.1 Introduction 32
    • 5.1.2 Revenue 32
    • 5.1.3 Treatment Algorithm 36
    • 5.1.4 Annual Cost of Treatment 36
    • 5.1.5 Treatment Usage Pattern 37
    • 5.1.6 Drivers and Barriers for the Rheumatoid Arthritis Therapeutics Market 39
  • 5.2 Multiple Sclerosis Therapeutics Market 41
    • 5.2.1 Introduction 41
    • 5.2.2 Revenue 42
    • 5.2.3 Treatment Algorithm 46
    • 5.2.4 Annual Cost of Treatment 47
    • 5.2.5 Treatment Usage Patterns 48
    • 5.2.6 Drivers and Barriers for Multiple Sclerosis Therapeutics Market 49
  • 5.3 Psoriasis Therapeutics Market 51
    • 5.3.1 Introduction 51
    • 5.3.2 Revenue 52
    • 5.3.3 Treatment Algorithm 55
    • 5.3.4 Annual Cost of Treatment 55
    • 5.3.5 Treatment Usage Pattern 56
    • 5.3.6 Drivers and Barriers for Psoriasis Therapeutics Market 58
  • 5.4 Inflammatory Bowel Disease Therapeutics Market 59
    • 5.4.1 Introduction 59
    • 5.4.2 Revenue 60
    • 5.4.3 Treatment Algorithm 63
    • 5.4.4 Annual Cost of Treatment 65
    • 5.4.5 Treatment Usage Pattern 66
    • 5.4.6 Drivers and Barriers for the Inflammatory Bowel Disease Therapeutics Market 68
  • 5.5 Systemic Lupus Erythematosus Therapeutics Market 69
    • 5.5.1 Introduction 69
    • 5.5.2 Revenue 70
    • 5.5.3 Treatment Algorithm 73
    • 5.5.4 Annual Cost of Treatment 74
    • 5.5.5 Treatment Usage Pattern 75
    • 5.5.6 Drivers and Barriers for the Systemic Lupus Erythematosus Therapeutics Market 78

6 Autoimmune Disorders Therapeutics Market to 2017: Pipeline Analysis 80

  • 6.1 Introduction 80
  • 6.2 Autoimmune Disorders Therapeutics Market - Pipeline Assessment by Clinical Phase of Development 82
    • 6.2.1 Filed Molecules 82
    • 6.2.2 Phase III 85
    • 6.2.3 Phase II 107
    • 6.2.4 Phase I 115
    • 6.2.5 Preclinical Phase 118
    • 6.2.6 Discovery Phase 126
  • 6.3 Profiles of Promising Molecules in the Autoimmune Disorders Therapeutics Market 128
    • 6.3.1 ABT-874 128
    • 6.3.2 Actemra 128
    • 6.3.3 Biferonex 129
    • 6.3.4 Fampyra 130
    • 6.3.5 Iguratimod 130
    • 6.3.6 LAS41002 131
    • 6.3.7 MAbThera 132
    • 6.3.8 Rebif 133
    • 6.3.9 Remicade 134
    • 6.3.10 Simponi 135
    • 6.3.11 T-614 136
    • 6.3.12 Zushima 137

7 Autoimmune Disorders Therapeutics Market to 2017: Competitive Profiling 138

  • 7.1 Market Share Analysis 138
  • 7.2 Competitive Profiling 138
    • 7.2.1 Abbott Laboratories 138
    • 7.2.2 Pfizer Inc. 139
    • 7.2.3 Johnson & Johnson 141
    • 7.2.4 Biogen Idec Inc. 142
    • 7.2.5 Amgen Inc. 143
    • 7.2.6 Bayer AG 145
    • 7.2.7 Sanofi 146

8 Autoimmune Disorders Therapeutics Market to 2017: Strategic Consolidations 148

  • 8.1 Overview 148
  • 8.2 Mergers and Acquisitions 149
    • 8.2.1 Segmentation by Indication 149
    • 8.2.2 Segmentation by Year 150
    • 8.2.3 Segmentation by Deal Type 151
    • 8.2.4 Segmentation by Deal Value 152
    • 8.2.5 Segmentation by Geography 154
  • 8.3 Co-development Deals 155
    • 8.3.1 Segmentation by Indication 155
    • 8.3.2 Segmentation by Year 156
    • 8.3.3 Segmentation by Value 157
    • 8.3.4 Segmentation by Geography 158
    • 8.3.5 Summary of Co-development Deals 161
  • 8.4 Licensing Deals 163
    • 8.4.1 Segmentation by Indication 163
    • 8.4.2 Segmentation by Year 164
    • 8.4.3 Segmentation by Value 165
    • 8.4.4 Segmentation by Geography 166
    • 8.4.5 Summary of Licensing Deals 173

9 Autoimmune Disorders Therapeutics Market to 2017: Appendix 176

  • 9.1 Market Definitions 176
  • 9.2 Abbreviations 176
  • 9.3 Sources 178
  • 9.4 Research Methodology 178
    • 9.4.1 Coverage 179
    • 9.4.2 Secondary Research 179
    • 9.4.3 Primary Research 179
  • 9.5 Therapeutic Landscape 180
    • 9.5.1 Epidemiology-based Forecasting 180
    • 9.5.2 Market Size by Geography 182
  • 9.6 Geographical Landscape 183
  • 9.7 Pipeline Analysis 183
  • 9.8 Competitive Landscape 183
  • 9.9 Expert Panel Validation 183
  • 9.10 Contact Us 183
  • 9.11 Disclaimer 183

List of Tables

  • Table 1: Autoimmune Disorders Therapeutics Market, Global, Revenue ($bn), 2002-2010 14
  • Table 2: Autoimmune Disorders Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2017 14
  • Table 3: Autoimmune Disorders Therapeutics Market, Global Annual Cost of Treatment ($), 2002-2010 15
  • Table 4: Autoimmune Disorders Therapeutics Market, Global Annual Cost of Treatment ($), 2010-2017 15
  • Table 5: Autoimmune Disorders Therapeutics Market, Treatment Usage Patterns (millions), 2002-2010 16
  • Table 6: Autoimmune Disorders Therapeutics Market, Treatment Usage Patterns (millions), 2010-2017 17
  • Table 7: Autoimmune Disorders Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2010 18
  • Table 8: Autoimmune Disorders Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2010-2017 19
  • Table 9: Autoimmune Disorders Therapeutics Market, The US, Revenue ($bn), 2002-2010 20
  • Table 10: Autoimmune Disorders Therapeutics Market, The US, Revenue ($bn), 2010-2017 20
  • Table 11: Autoimmune Disorders Therapeutics Market, The US, Annual Cost of Treatment ($), 2002-2010 21
  • Table 12: Autoimmune Disorders Therapeutics Market, The US, Annual Cost of Treatment ($), 2010-2017 21
  • Table 13: Autoimmune Disorders Therapeutics Market, The US, Treatment Usage Patterns (millions), 2002-2010 22
  • Table 14: Autoimmune Disorders Therapeutics Market, The US, Treatment Usage Patterns (millions), 2010-2017 22
  • Table 15: Autoimmune Disorders Therapeutics Market, Top Five Countries of Europe, Revenue ($bn), 2002-2010 23
  • Table 16: Autoimmune Disorders Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($bn), 2010-2017 23
  • Table 17: Autoimmune Disorders Therapeutics Market, Top Five Countries of Europe, Revenue ($bn), 2002-2010 24
  • Table 18: Autoimmune Disorders Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($bn), 2010-2017 24
  • Table 19: Autoimmune Disorders Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2010 25
  • Table 20: Autoimmune Disorders Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2010-2017 25
  • Table 21: Autoimmune Disorders Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (millions), 2002-2010 26
  • Table 22: Autoimmune Disorders Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (millions), 2010-2017 27
  • Table 23: Autoimmune Disorders Therapeutics Market, Japan, Revenue ($bn), 2002-2010 28
  • Table 24: Autoimmune Disorders Therapeutics Market, Japan, Revenue Forecast ($bn), 2010-2017 28
  • Table 25: Autoimmune Disorders Therapeutics Market, Japan, Annual Cost of Treatment ($), 2002-2010 29
  • Table 26: Autoimmune Disorders Therapeutics Market, Japan, Annual Cost of Treatment ($), 2010-2017 29
  • Table 27: Autoimmune Disorders Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2002-2010 30
  • Table 28: Autoimmune Disorders Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2010-2017 31
  • Table 29: Rheumatoid Arthritis Therapeutics Market, Global, Revenue ($bn), 2002-2010 32
  • Table 30: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Forecast ($bn), 2010-2017 33
  • Table 31: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2010 34
  • Table 32: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2010-2017 34
  • Table 33: Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010 37
  • Table 34: Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017 37
  • Table 35: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2010 38
  • Table 36: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2017 38
  • Table 37: Multiple Sclerosis Therapeutics Market, Global, Revenue ($bn), 2002-2010 42
  • Table 38: Multiple Sclerosis Therapeutics Market, Global, Revenue Forecast ($bn), 2010-2017 43
  • Table 39: Multiple Sclerosis Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2010 44
  • Table 40: Multiple Sclerosis Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2010-2017 44
  • Table 41: Multiple Sclerosis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010 47
  • Table 42: Multiple Sclerosis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017 47
  • Table 43: Multiple Sclerosis Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2002-2010 48
  • Table 44: Multiple Sclerosis Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2010-2017 49
  • Table 45: Psoriasis Therapeutics Market, Global, Revenue ($bn), 2002-2010 52
  • Table 46: Psoriasis Therapeutics Market, Global, Revenue Forecast ($bn), 2010-2017 52
  • Table 47: Psoriasis Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2010 53
  • Table 48: Psoriasis Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2010-2017 54
  • Table 49: Psoriasis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010 56
  • Table 50: Psoriasis Therapeutics Market, Global, Annual Cost of Treatment($), 2010-2017 56
  • Table 51: Psoriasis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2010 57
  • Table 52: Psoriasis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2017 57
  • Table 53: Inflammatory Bowel Disease Therapeutics Market, Global, Revenue ($bn), 2002-2010 60
  • Table 54: Inflammatory Bowel Disease Therapeutics Market, Global, Revenue Forecast ($bn), 2010-2017 60
  • Table 55: Inflammatory Bowel Disease Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2010 61
  • Table 56: Inflammatory Bowel Disease Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2010-2017 62
  • Table 57: Inflammatory Bowel Disease Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010 65
  • Table 58: Inflammatory Bowel Disease Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017 65
  • Table 59: Inflammatory Bowel Disease Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2002-2010 66
  • Table 60: Inflammatory Bowel Disease Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2010-2017 67
  • Table 61: Systemic Lupus Erythematosus Therapeutics Market, Global, Revenue ($m), 2002-2010 70
  • Table 62: Systemic Lupus Erythematosus Therapeutics Market, Global, Revenue Forecasts ($m), 2010-2017 70
  • Table 63: Systemic Lupus Erythematosus Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2010 71
  • Table 64: Systemic Lupus Erythematosus Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2010-2017 72
  • Table 65: Systemic Lupus Erythematosus Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010 74
  • Table 66: Systemic Lupus Erythematosus Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017 74
  • Table 67: Systemic Lupus Erythematosus Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2002-2010 75
  • Table 68: Systemic Lupus Erythematosus Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2010-2017 76
  • Table 69: Autoimmune Disorders Therapeutics Market, Global, Pipeline Analysis, New Drug Application Filed Molecules, 2011 82
  • Table 70: Autoimmune Disorders Therapeutics Market, Global, Pipeline Analysis, Phase III, 2011 85
  • Table 71: Autoimmune Disorders Therapeutics Market, Global, Pipeline Analysis, Phase II, 2011 107
  • Table 72: Autoimmune Disorders Therapeutics Market, Global, Pipeline Analysis, Phase I, 2011 115
  • Table 73: Autoimmune Disorders Therapeutics Market, Global, Pipeline Analysis, Preclinical Phase, 2011 118
  • Table 74: Autoimmune Disorders Therapeutics Market, Global, Pipeline Analysis, Discovery Phase, 2011 126
  • Table 75: Autoimmune Disorders Therapeutics Market, Global, Deals by Type, (%), 2009-2011 148
  • Table 76: Autoimmune Disorders Therapeutics Market, Global, M&A Deals by Indication, 2009-2011 149
  • Table 77: Autoimmune Disorders Therapeutics Market, Global, Number of M&A Deals, 2009-2011 150
  • Table 78: Autoimmune Disorders Therapeutics Market, Global, M&A Deals by Deal Type (%), 2009-2011 151
  • Table 79: Autoimmune Disorders Therapeutics Market, Global, M&A Deals, by Value ($m), 2009-2011 152
  • Table 80: Autoimmune Disorders Therapeutics Market, Global, Number of Co-Development Deals, 2009-2011 156
  • Table 81: Autoimmune Disorders Therapeutics Market, Global, Co-Developments Deals by Value, 2009-2011 157
  • Table 82: Autoimmune Disorders Therapeutics Market, Global, Co-Development Deals by Geography, 2009-2011 158
  • Table 83: Autoimmune Disorders Therapeutics Market, Global, Co-development Deals by Geography, 2009-2011 159
  • Table 84: Autoimmune Disorders Therapeutics Market, Global, Licensing Agreements by Indication, 2009-2011 164
  • Table 85: Autoimmune Disorders Therapeutics Market, Global, Licensing Agreements by Indication (%), 2009-2011 164
  • Table 86: Autoimmune Disorders Therapeutics Market, Global, Licensing Agreements by Value, 2009-2011 165
  • Table 87: Autoimmune Disorders Therapeutics Market, Licensing Deals by Geography, 2009-2011 167

List of Figures

  • Figure 1: Autoimmune Disorders Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017 14
  • Figure 2: Autoimmune Disorders Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017 15
  • Figure 3: Autoimmune Disorders Therapeutics Market, Treatment Usage Patterns (millions), 2002-2017 16
  • Figure 4: Autoimmune Disorders Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2017 18
  • Figure 5: Autoimmune Disorders Therapeutics Market, The US, Revenue ($bn), 2002-2017 19
  • Figure 6: Autoimmune Disorders Therapeutics Market, The US, Annual Cost of Treatment ($), 2002-2017 20
  • Figure 7: Autoimmune Disorders Therapeutics Market, The US, Treatment Usage Patterns (millions), 2002-2017 21
  • Figure 8: Autoimmune Disorders Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($bn), 2002-2017 23
  • Figure 9: Autoimmune Disorders Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($bn), 2002-2017 24
  • Figure 10: Autoimmune Disorders Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2017 25
  • Figure 11: Autoimmune Disorders Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (millions), 2002-2017 26
  • Figure 12: Autoimmune Disorders Therapeutics Market, Japan, Revenue Forecast ($bn), 2002-2017 28
  • Figure 13: Autoimmune Disorders Therapeutics Market, Japan, Annual Cost of Treatment ($), 2002-2017 29
  • Figure 14: Autoimmune Disorders Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2002-2017 30
  • Figure 15: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017 32
  • Figure 16: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2017 33
  • Figure 17: Rheumatoid Arthritis Therapeutics Market, Global, Branded & Generic Market Share (%), 2010 and 2017 35
  • Figure 18: Rheumatoid Arthritis Therapeutics Market, Rheumatoid Arthritis, Treatment Algorithm 36
  • Figure 19: Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017 36
  • Figure 20: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2017 37
  • Figure 21: Rheumatoid Arthritis Therapeutics Market, Drivers and Barriers 39
  • Figure 22: Multiple Sclerosis Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017 42
  • Figure 23: Multiple Sclerosis Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2017 43
  • Figure 24: Multiple Sclerosis Therapeutics Market, Global, Branded & Generic Market Share (%), 2010 and 2017 45
  • Figure 25: Multiple Sclerosis Therapeutics Market, Multiple Sclerosis, Treatment Algorithm 46
  • Figure 26: Multiple Sclerosis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017 47
  • Figure 27: Multiple Sclerosis Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2002-2017 48
  • Figure 28: Multiple Sclerosis Therapeutics Market, Drivers and Barriers 50
  • Figure 29: Psoriasis Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017 52
  • Figure 30: Psoriasis Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2017 53
  • Figure 31: Psoriasis Therapeutics Market, Global, Branded & Generic Market Share (%), 2010 and 2017 54
  • Figure 32: Psoriasis Therapeutics Market, Psoriasis, Treatment Algorithm 55
  • Figure 33: Psoriasis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017 55
  • Figure 34: Psoriasis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2017 56
  • Figure 35: Psoriasis Therapeutics Market, Drivers and Barriers 58
  • Figure 36: Inflammatory Bowel Disease Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017 60
  • Figure 37: Inflammatory Bowel Disease Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2017 61
  • Figure 38: Inflammatory Bowel Disease Therapeutics Market, Global, Branded & Generic Market Share (%), 2010 and 2017 62
  • Figure 39: Inflammatory Bowel Disease Therapeutics Market, Ulcerative Colitis, Treatment Algorithm 63
  • Figure 40: Inflammatory Bowel Disease Therapeutics Market, Crohn's Disease, Treatment Algorithm 64
  • Figure 41: Inflammatory Bowel Disease Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017 65
  • Figure 42: Inflammatory Bowel Disease Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2002-2017 66
  • Figure 43: Inflammatory Bowel Disease Therapeutics Market, Global, Drivers and Barriers 68
  • Figure 44: Systemic Lupus Erythematosus Therapeutics Market, Global, Revenue Forecasts ($m), 2002-2017 70
  • Figure 45: Systemic Lupus Erythematosus Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2017 71
  • Figure 46: Systemic Lupus Erythematosus Therapeutics Market, Global, Branded & Generic Market Share (%), 2010 and 2017 72
  • Figure 47: Systemic Lupus Erythematosus Therapeutics Market, Systemic Lupus Erythematosus, Treatment Algorithm 73
  • Figure 48: Systemic Lupus Erythematosus Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017 74
  • Figure 49: Systemic Lupus Erythematosus Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2002-2017 75
  • Figure 50: Systemic Lupus Erythematosus Therapeutics Market, Global, Drivers and Barriers 79
  • Figure 51: Autoimmune Disorders Therapeutics Market, Global, R&D Pipeline by Indications (%), 2011 80
  • Figure 52: Autoimmune Disorders Therapeutics Market, Global, R&D Pipeline by Phase (%), 2011 81
  • Figure 53: Autoimmune Disorders Therapeutics Market, Global, Market Share of Top Companies (%), 2010 138
  • Figure 54: Autoimmune Disorders Therapeutics Market, Global, SWOT Analysis, Abbott, 2011 139
  • Figure 55: Autoimmune Disorders Therapeutics Market, Global, SWOT Analysis, Pfizer Inc., 2011 140
  • Figure 56: Autoimmune Disorders Therapeutics Market, Global, SWOT Analysis, Johnson & Johnson, 2011 141
  • Figure 57: Autoimmune Disorders Therapeutics Market, Global, SWOT Analysis, Biogen Idec Inc., 2011 143
  • Figure 58: Autoimmune Disorders Therapeutics Market, Global, SWOT Analysis, Amgen Inc., 2011 144
  • Figure 59: Autoimmune Disorders Therapeutics Market, Global, SWOT Analysis, Bayer AG, 2011 145
  • Figure 60: Autoimmune Disorders Therapeutics Market, Global, SWOT Analysis, Sanofi, 2011 147
  • Figure 61: Autoimmune Disorders Therapeutics Market, Global, Deals by Type, (%), 2009-2011 148
  • Figure 62: Autoimmune Disorders Therapeutics Market, Global, M&A Deals by Indication (%), 2009-2011 149
  • Figure 63: Autoimmune Disorders Therapeutics Market, Global, Number of M&A Deals, 2009-2011 150
  • Figure 64: Autoimmune Disorders Therapeutics Market, Global, M&A Deals by Deal Type (%), 2009-2011 151
  • Figure 65: Autoimmune Disorders Therapeutics Market, M&A Deals, by Value (%) 2009-2011 152
  • Figure 66: Autoimmune Disorders Therapeutics Market, M&A Deals, by Geography (%), 2009-2011 154
  • Figure 67: Autoimmune Disorders Therapeutics Market, Global, Co-Development Deals by Indication (%), 2009-2011 155
  • Figure 68: Autoimmune Disorders Therapeutics Market, Global, Number of Co-Development Deals, 2009-2011 156
  • Figure 69: Autoimmune Disorders Therapeutics Market, Global, Co-Developments Deals by Value (%), 2009-2011 157
  • Figure 70: Autoimmune Disorders Therapeutics Market, Global, Co-Development Deals by Geography (%), 2009-2011 158
  • Figure 71: Autoimmune Disorders Therapeutics Market, Global, Licensing Agreements by Indication (%), 2009-2011 163
  • Figure 72: Autoimmune Disorders Therapeutics Market, Global, Licensing Agreements by Indication (%), 2009-2011 164
  • Figure 73: Autoimmune Disorders Therapeutics Market, Global, Licensing Agreements by Value (%), 2009-2011 165
  • Figure 74: Autoimmune Disorders Therapeutics Market, Licensing Deals by Geography (%), 2009-2011 166
  • Figure 75: GBI Research Market Forecasting Model 182
Back to Top